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Abstract
Introduction: The effect of parenteral fish oil in septic patients is not widely studied. This study investigated the effects 
of parenteral fish oil on plasma phospholipid fatty acids, inflammatory mediators, and clinical outcomes.
Methods: Twenty-five patients with systemic inflammatory response syndrome or sepsis, and predicted to need 
parenteral nutrition were randomized to receive either a 50:50 mixture of medium-chain fatty acids and soybean oil or 
a 50:40:10 mixture of medium-chain fatty acids, soybean oil and fish oil. Parenteral nutrition was administrated 
continuously for five days from admission. Cytokines and eicosanoids were measured in plasma and in 
lipopolysaccharide-stimulated whole blood culture supernatants. Fatty acids were measured in plasma 
phosphatidylcholine.
Results: Fish oil increased eicosapentaenoic acid in plasma phosphatidylcholine (P < 0.001). Plasma interleukin (IL)-6 
concentration decreased significantly more, and IL-10 significantly less, in the fish oil group (both P < 0.001). At Day 6 
the ratio PO2/FiO2 was significantly higher in the fish oil group (P = 0.047) and there were fewer patients with PO2/FiO2 
<200 and <300 in the fish oil group (P = 0.001 and P = 0.015, respectively). Days of ventilation, length of intensive care 
unit (ICU) stay and mortality were not different between the two groups. The fish oil group tended to have a shorter 
length of hospital stay (22 ± 7 vs. 55 ± 16 days; P = 0.079) which became significant (28 ± 9 vs. 82 ± 19 days; P = 0.044) 
when only surviving patients were included.
Conclusions: Inclusion of fish oil in parenteral nutrition provided to septic ICU patients increases plasma 
eicosapentaenoic acid, modifies inflammatory cytokine concentrations and improves gas exchange. These changes 
are associated with a tendency towards shorter length of hospital stay.
Trials Registration: Clinical Trials Registration Number ISRCTN89432944
Introduction
Sepsis results from a host inflammatory response to
infection [1] and is characterised by high circulating con-
centrations of inflammatory cytokines such as tumor
necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-
8 [1,2]. Although conditions other than infections can
trigger a state of hyperinflammation, sepsis requires spe-
cial attention since even with current treatments it is
often associated with very high mortality. Between the
years 1979 and 2000, total sepsis-related mortality in the
United States rose from 22 to 44 per 100,000 population
[3], accounting for 9% of the overall annual mortality [4,5]
with an enormous economic cost [6].
Septic patients receive the bulk of their nutrition by the
parenteral route. Recently there has been increased inter-
est in the lipid component of parenteral nutrition with
the realisation that this not only supplies energy and
essential building blocks, but may also provide molecules
(that is, fatty acids) that are bioactive [7,8]. Traditionally
used lipid emulsions are based solely upon soybean oil,
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which is rich in the n-6 fatty acid linoleic acid, or a 50:50
mix of vegetable oil rich in medium-chain saturated fatty
acids and soybean oil (often termed MCT/LCT to indi-
cate the mixture of medium chain and long chain triglyc-
erides). More recently fish oil, which contains very long
chain n-3 fatty acids, has been introduced into some lipid
emulsions [9,10]. The rationale is partly that n-3 fatty
acids act to reduce inflammatory responses [11], which
may be promoted by an excessive or unbalanced supply of
n-6 fatty acids. Compared with n-6 fatty acid rich vegeta-
ble oil, fish oil reduces the metabolic signs of endotox-
emia in experimental animals [12], and lowers plasma
cytokine concentrations [13] and improves survival
[12,14]. Fish oil containing parenteral nutrition has been
used in surgical patients demonstrating possible
improvements in immune function [15,16] and reduced
inflammation [16,17] which have been linked to a shorter
stay in the intensive care unit (ICU) [16] and in hospital
[16,18]. However there are few studies of fish oil contain-
ing lipid emulsions in septic patients in the ICU. Tappy et
al. [19] demonstrated that parenteral fish oil is well toler-
ated and has only limited metabolic effects in critically ill
patients, while Antebi et al. [20] showed that the use of
fish oil in ICU patients requiring total parenteral nutri-
tion may be associated with better liver function and
improved antioxidant status. In two studies, Mayer et al.
[21,22] reported diminished inflammation, including
reduced TNF-α, IL-1β, IL-6, IL-8 and IL-10 production
by cultured monocytes, in septic patients receiving a soy-
bean oil-fish oil mix compared to those receiving soybean
oil alone. These two studies did not report any clinical
outcomes. Heller et al. [23] reported a dose-response
effect of parenteral fish oil on antibiotic demand, length
of hospital stay and mortality in critically ill patients.
However, this latter study was not controlled. Recently,
Friesecke et al. [24] reported that use of a mixed MCT/
LCT/fish oil lipid emulsion in critically ill ICU patients
had no effect on inflammatory markers, or on clinical
outcomes including infections, ventilation requirement,
o r  I CU  o r  h o s p i t a l  s t a y  c o m p a r e d  w i t h  M C T / L CT .  I n
contrast, use of fish oil in parenteral nutrition in severe
pancreatitis patients resulted in a decreased inflamma-
tory response, improved respiratory function and short-
ened Continuous Renal Replacement Therapy time [25].
Thus, there is only limited, and contradictory, informa-
tion on the influence of fish oil containing parenteral
nutrition in septic ICU patients on markers of inflamma-
tion and on clinical endpoints. However, studies of
enteral nutrition providing fish oil, in addition to other
potentially active ingredients, have demonstrated
reduced inflammation, improved gas exchange and
improved clinical outcome in patients with acute respira-
tory distress syndrome and/or acute lung injury [26-28].
This study was designed to investigate the potential
benefits of using a parenteral lipid emulsion that includes
fish oil in septic patients in the ICU. The outcomes were
plasma phospholipid fatty acid profile, inflammatory
mediators in plasma and produced by lipopolysaccha-
ride-stimulated whole blood, routine biochemical and
physiological markers, gas exchange and clinical out-
c o m e s .  I t  w a s  h y p o t h e s i s e d  t h a t  i n c l u s i o n  o f  f i s h  o i l
would increase the n-3 fatty acid content of plasma phos-
pholipids, would decrease circulating inflammatory
cytokine concentrations and would reduce length of ICU
and hospital stay.
Materials and methods
Study design
This study was a randomized, single blinded investigation
of a parenteral lipid emulsion that contained fish oil in
comparison with one that did not in patients admitted to
a medical ICU with diagnosed sepsis. Patients were
recruited from the ICU of Hospital Padre Américo, Pena-
fiel, Portugal. The study was approved by the Ethics Com-
mittee  Comissão de Ética para a Saúde from Hospital
Padre Américo and was conducted in accordance with
the Helsinki Declaration. Written informed consent was
obtained from each patient's closest relative.
Patient selection
Twenty-five patients with diagnosed systemic inflamma-
tory response syndrome (SIRS) or sepsis [1] and who
were predicted to need parenteral nutrition (severe pan-
creatitis, multiorgan failure, excisional surgery) were
recruited at the time of admission to the ICU. Patients
were recruited between March and December 2007. Sep-
sis was defined as suspected or proven infection plus
SIRS (that is, presence of pyrexia, tachycardia, tachypnea
and/or leukocytosis). Severe sepsis was defined as sepsis
with organ dysfunction (hypotension, hypoxemia, oligu-
ria, metabolic acidosis, and/or thrombocytopenia). Septic
shock was defined as severe sepsis with hypotension
despite adequate fluid resuscitation. Once identified as
eligible to enter the study, patients were randomized by a
sealed envelope to receive either a 50:50 (vol/vol) mixture
of an oil rich in medium-chain fatty acids and soybean oil
(termed MCT/LCT) (provided as a component of Nutri-
flex LipidSpecial®, B. Braun, Barcarena, Portugal) or a
50:40:10 (vol/vol/vol) mixture of an oil rich in medium-
chain fatty acids, soybean oil and fish oil (termed fish oil)
(provided as Lipolus®, B. Braun, Portugal). The principal
differences are the presence of the long chain n-3 fatty
acids eicosapentaenoic acid (EPA; 20:5n-3) and docosa-
hexaenoic acid (DHA; 22:6n-3) in the fish oil containing
emulsion where they contribute about 3.6% of fatty acids
(2.5% of fatty acids as EPA and 1.1% of fatty acids as
DHA) [29]. Nutriflex LipidSpecial is the routine meansBarbosa et al. Critical Care 2010, 14:R5
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for supplying parenteral nutrition in Hospital Padre
Américo ICU. Nutriflex LipidSpecial provides lipid
(MCT/LCT emulsion), glucose and amino acids via a 1.25
liter three chamber bag. Lipoplus (250 ml) was added into
1 liter Nutriflex Special® (B. Braun, Portugal) two chamber
bags that provided glucose and amino acids. Nutriflex
LipidSpecial had a lower glucose content than Nutriflex
Special containing Lipoplus (144 g/l vs. 195 g/l), while the
amino acid content was similar (57.4 g/l vs. 56 g/l). The
amount of lipid contained within the final mixture was
the same in both groups (40 g/l). Dipeptiven® (Fresenius-
Kabi, Carnaxide, Portugal) (50 ml/1250 ml bag) was
included in both regimens. Both groups received electro-
lytes and vitamins.
Two of the 25 patients recruited did not start on paren-
teral nutrition and so are excluded from the study. Char-
acteristics of the 23 patients who started on parenteral
nutrition in the two groups are summarised in Table 1.
From the 23 patients analysed, 13 received fish oil and 10
received MCT/LCT. Parenteral nutrition was adminis-
trated continuously over 24 hours, starting on the day
after admission when the patient was hemodynamically
stable, or if not, as soon as possible (Day 1 is defined as
when parenteral nutrition was started). Blood samples
were collected on admission, immediately prior to start-
ing parenteral nutrition (that is, Day 1), 24 h after initiat-
ing parenteral nutrition (Day 2) and five days after
initiating parenteral nutrition (Day 6). Blood was col-
lected between 08:30 to 9:00 hours via an arterial line into
ethylenediaminetetraacetic acid or lithium heparin.
Enteral nutrition was initiated as soon as possible, but
for all patients this was beyond Day 6; enteral feeding was
initiated as a mixed regimen with parenteral nutrition
which used the same lipid emulsion as had been used for
the study duration. For all patients the enteral feed used
was Fresubin Original (Freseius-Kabi, Portugal); Fresubin
Original contains fish oil and will provide 0.5 g of EPA
plus DHA per 1,500 kcal.
Nutritional assessment
Caloric intake was calculated using the Harris-Benedict
[30] formula using a stress factor between 1.2 and 1.3.
Weight was obtained at admission using a Hill-Rom® bed
(Hill-Rom Total Care, Batesville, IN, USA) which has a
previously calibrated balance incorporated. Height was
measured with the patient lying flat in bed.
Routine laboratory measurements
Full blood count, biochemistry and coagulation were rou-
tinely assessed. Blood was centrifuged at 2,000 rpm for 15
minutes to obtain plasma which was stored at -70°C until
analysis (within nine months).
Whole blood culture and plasma collection
Whole blood was cultured essentially as described by
Yaqoob et al. [31]. Whole blood was collected into lith-
ium heparin and diluted 1:10 in Roswell Park Memorial
Institute medium with 2 mmol/l L-glutamine and antibi-
otics (Sigma-Aldrich, Schnelldorf, Germany). The diluted
blood was cultured in duplicate, with and without 10 μg/
Table 1: Characteristics of the patients in the two treatment groups
Fish oil group (n = 13) MCT/LCT group (n = 10)
Age range (years) 54 to 80 32 to 79
Age (years) 70 ± 2* 57 ± 5
Sex: male/female (n) 5/8 4/6
Height (m) 1.59 ± 0.1 1.63 ± 0.06
Weight (kg) 73.3 ± 18.01 76.8 ± 21.28
Body mass index (kg/m2) 28.9 ± 1.7 28.5 ± 2.6
Admitted from: Operating theatre/
Emergency/Ward (n)
9/3/1 6/3/1
SAPS II 47.5 ± 5 41.6 ± 6.5
Sequential organ failure assessment score 9.5 ± 0.9 8.9 ± 1.2
Primary diagnosis: Sepsis/Severe sepsis/
Septic shock (n)
8/4/1 5/2/3
Secondary Diagnosis: Cardiovascular/
Respiratory/Renal/Gastric/Mental/
Metabolic (n)
9/1/1/2/0/0 7/0/2/2/2/1
Data are shown for patients who received parenteral nutrition (n = 23).
SAPS - Simplified Acute Physiology Score; *P = 0.019 vs. MCT/LCTBarbosa et al. Critical Care 2010, 14:R5
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ml of E. coli 0111:B4 lipopolysaccharide (LPS) (Sigma-
Aldrich, Schnelldorf, Germany). Culture plates were
incubated for 24 h in a 95% air 5% CO2 atmosphere and at
37°C. After this, the supernatant medium was collected
and stored at -70°C until analysis (within nine months).
Cytokine and eicosanoid analyses
Cytokines, prostaglandin (PG) E2 and leukotriene (LT) B4
were measured in plasma and cytokines and PGE2 in
whole blood culture supernatants. Cytokines and eico-
sanoids were measured using enzyme-linked immuno-
sorbent assays (ELISA) and following the manufacturer's
instructions. IL-1β, IL-6, IL-10 and TNF-α ELISA kits
were from Invitrogen (Paisley, UK), PGE2  ELISA kits
from R&D Systems (Abingdon, UK) and LTB4 ELISA kits
were from Cayman Chemical (Ann Arbor, MI, USA).
Lower limits of detection were: IL-1β 0.06 pg/ml, IL-6
104 fg/ml, IL-10 0.2 pg/ml, TNF-α 0.09 pg/ml, PGE2 27.5
pg/ml, and LTB4 4 pg/ml.
Fatty acid composition of plasma phosphatidylcholine
Fatty acid composition of plasma phospholipids (phos-
phatidylcholine; PC) was determined by gas chromatog-
raphy as described [32].
Statistical analysis
Data are presented as mean ± SEM, unless indicated oth-
erwise. Statistical analyses were performed using SPSS
version 14 (SPSS, Chicago, IL, USA). One factor ANOVA
was used to analyse changes over time within a treatment
group. Student's t-test was used for comparisons between
time points and for comparisons between groups at a par-
ticular time point; equal variances were not assumed.
Linear correlations were determined as Pearson's correla-
tion coefficients. In all cases, a value of P < 0.05 was taken
to indicate statistical significance.
Results
Energy and nutrient intakes
Energy, lipid, and amino acid intakes did not differ signif-
icantly between the groups (Table 2). However, glucose
intake was significantly higher in the fish oil group (Table
2). The fish oil group received an average of 6.4 g/d of fish
oil (Table 2), providing an average of 1.6 g EPA plus 0.7 g
DHA/d (that is, 2.3 g long chain n-3 fatty acids/d).
Plasma phosphatidylcholine fatty acid composition
The fatty acid composition of plasma PC was measured
as an indicator of n-6 and n-3 fatty acid status. Plasma PC
contributes about 75% of plasma phospholipid [33] and
functions as a transport pool of fatty acids delivering
them to target tissues like leukocytes. The concentration
of the long chain n-3 fatty acid EPA (20:5n-3) was
Table 2: Energy and nutrient intake in the two treatment groups
Fish oil group MCT/LCT group
Energy intake (kcal/d) 2057 ± 418 1857 ± 255
(kcal/kg/d) 29.3 ± 7.6 25.3 ± 5.6
Amino acid intake† (kcal/d) 329.1 ± 67.0 356.6 ± 50.2
(g/d) 82.3 ± 16.8 89.2 ± 12.6
(g/kg/d) 1.17 ± 0.30 1.22 ± 0.28
Glucose intake (kcal/d) 1151 ± 234** 909.8 ± 125.0
(g/d) 287.9 ± 58.6** 227.5 ± 31.3
(g/kg/d) 4.10 ± 1.07* 3.10 ± 0.69
Total lipid intake (kcal/d) 575.9 ± 117.3 594.2 ± 81.7
(g/d) 63.9 ± 13.0 66.0 ± 9.1
(g/kg/d) 0.91 ± 0.24 0.90 ± 0.20
Lipid intake as fish oil (kcal/d) 57.59 ± 11.7*** 0
(g/d) 6.4 ± 1.3*** 0
(g/kg/d) 0.09 ± 0.02*** 0
Data are mean ± SEM; †Excluding glutamine and alanine provided in dipeptiven
*P = 0.018; **P < 0.01; ***P < 0.001 vs. MCT/LCTBarbosa et al. Critical Care 2010, 14:R5
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increased in the fish oil group after supplementation such
that levels were higher at Day 6 than at admission (P <
0.001), at Day 1 (p < 0.001) and at Day 2 (P = 0.003) (Fig-
ure 1a). EPA was higher in the fish oil group than in the
MCT/LCT group at Day 6 (P < 0.001). The concentra-
tions of DHA (22:6n-3) and of the long chain n-6 fatty
acid arachidonic acid (20:4n-6) did not differ between the
two groups (Figure 1b and 1c).
Plasma cytokine and eicosanoid concentrations
Plasma cytokine, PGE2 and LTB4 concentrations did not
differ between the two groups prior to initiation of paren-
teral nutrition (that is, Day 1) (Table 3). Linear regression
demonstrated that both IL-1β and TNF-α decreased over
time in both groups (IL-1β: P = 0.035 and P = 0.010 in the
MCT/LCT and fish oil groups respectively; TNF-α: P =
0.036 and P = 0.005 in the MCT/LCT and fish oil groups
respectively). Plasma IL-6 concentration also decreased
over time in the fish oil group (P = 0.023). The changes in
concentrations of IL-1β, IL-6, IL-10, and TNF-α between
Day 6 and Day 1 were significantly different between
groups when concentration at Day 1 was adjusted for;
when concentration at Day 1, age and glucose supply
were adjusted for; and when concentration at Day 1, age,
glucose supply and simplified acute physiology score
(SAPS) II at entry were adjusted for (all P < 0.001; Table
3). The decrease in IL-6 concentration was greater in the
fish oil group while the decrease in IL-10 concentration
was smaller in the fish oil group (Table 3). The decreases
in IL-1β and TNF-α concentrations were similar between
the groups, but were significantly smaller in the fish oil
group (Table 3).
The concentrations (μg/ml) of (a) EPA, (b) DHA and (c) 
arachidonic acid in plasma phosphatidylcholine in the two 
treatment groups
Figure 1 The concentrations (μg/ml) of (a) EPA, (b) DHA and (c) 
arachidonic acid in plasma phosphatidylcholine in the two treat-
ment groups. *P < 0.001 vs. MCT/LCT at the same timepoint.
a)
Eicosapentaenoic Acid in Plasma PC
0
10
20
30
40
50
60
Admission             Day 1                   Day 2                  Day 6
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
u
g
/
m
l
)
Fish oil group
MCT/soybean group
b)
Docosahexaenoic Acid in Plasma PC
0
10
20
30
40
50
60
70
80
90
Admission           Day 1                  Day 2                Day 6
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
u
g
/
m
l
)
Fish oil group
MCT/soybean group
c)
Arachidonic Acid in Plasma PC
0
50
100
150
200
250
300
Admission             Day 1                   Day 2                 Day 6  
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
u
g
/
m
l
)
Fish oil group
MCT/soybean group
Table 3: Plasma cytokine and eicosanoid concentrations in the two treatment groups (pg/ml)
Fish oil group MCT/LCT group
Day 1 Day 6 - Day 1 Day 1 Day 6 - Day 1
IL-1β 5.0 ± 3.2 -3.8 ± 3.0* 5.7 ± 2.2 -4.2 ± 2.2
IL-6 8181 ± 5723 -4950 ± 6690* 1499 ± 732 -1242 ± 725
IL-10 44 ± 8 -29 ± 8* 85 ± 44 -64 ± 40
TNF-α 18.0 ± 3.1 -8.1 ± 3.6* 18.5 ± 5.1 -9.6 ± 4.9
PGE2 267 ± 126 391 ± 393 210 ± 134 513 ± 471
LTB4 338 ± 88 111 ± 147 421 ± 160 271 ± 148
Data are mean ± SEM
*P < 0.001 vs MCT/LCT group after adjusting for Day 1 value, or for Day 1 value, age and glucose supply, or for Day 1 value, age, glucose supply 
and SAPS II at entry.Barbosa et al. Critical Care 2010, 14:R5
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Cytokine and PGE2 production by LPS-stimulated whole 
blood cultures
Cytokine and PGE2 production by unstimulated and LPS-
stimulated whole blood cultures did not differ between
treatment groups at admission of patients or at any time
point thereafter, even after controlling for age, glucose
supply and SAPS II (data not shown). However, there was
a significant effect of time, but not of treatment and there
was no time × treatment interaction, on the LPS-stimu-
lated production of TNF-α, IL-1β, IL-6 and IL-10 (two-
factor ANOVA P = 0.002, 0.013, 0.001 and 0.008, respec-
tively). Linear regression demonstrated that production
of each of these cytokines increased with time, with a
similar increase in both groups (Pearson's linear correla-
tion coefficient = 0.394 (P < 0.001), 0.318 (P < 0.001),
0.416 (P < 0.001), 0.286 (P = 0.007) for TNF-α, IL-1β, IL-6
and IL-10, respectively).
Routine laboratory measurements
There were no differences between the treatment groups
with regard to blood leukocyte numbers, blood glucose
concentration, C-reactive protein concentration, partial
thrombin time, liver enzymes, and total bilirubin (Table
4). In the fish oil group blood monocyte numbers were
significantly higher at Day 6 (1.41 ± 0.41 × 103/μl) than at
admission (0.52 ± 0.09 × 103/μl; P = 0.017) and Day 2
(0.47 ± 0.11 × 103/μl; P = 0.006). However, blood mono-
cyte numbers did not differ between treatment groups at
any time point. Fibrinogen concentration was signifi-
cantly lower in the fish oil group at Day 2 (Table 4).
Gas exchange
At Day 6, partial pressure carbon dioxide (PCO2) and the
ratio partial pressure of oxygen/fraction of inspired oxy-
gen (PO2/FiO2) were significantly higher in the fish oil
group than in the MCT/LCT group (P = 0.033 and P =
0.047, respectively; Table 5), although the latter lost sig-
nificance when age and glucose supply or age, glucose
supply and SAPS II at entry were adjusted for. The pro-
portions of patients with PO2/FiO2 <200 and <300 at Day
6 were significantly lower in the fish oil group than the
MCT/LCT group (0% vs. 60% for <200 (P = 0.001; γ2 test)
Table 4: Routine laboratory parameters in the two treatment groups
Fish oil group MCT/LCT group
Admissio
n
(n = 13)
Day 1
(n = 13)
Day 2
(n = 13)
Day 6
(n = 11)
Admissio
n
(n = 10)
Day 1
(n = 10)
Day 2
(n = 10)
Day 6
(n = 10)
Leucocytes 
(103/μL)
14.6 ± 7.4 16.2 ± 9.2 14.2 ± 6.8 11.8 ± 5.4 17.7 ± 13.2 18.6 ± 
12.8
15.2 ± 
9.7
12.0 ± 6.0
Platelets 
(103/μL)
212 ± 158 180 ± 163 126 ± 138 138 ± 122 215 ± 131 241 ± 122 204 ± 
109
223 ± 150
Partial 
thrombin 
time 
(seconds)
46.2 ± 
14.8
55.9 ± 
21.5
66.5 ± 
41.5
77.1 ± 94.5 38 ± 18.8 44.6 ± 
20.7
40.6 ± 
12.8
34.8 ± 6.6
Fibrinogen 
(mg/dL)
271 ± 136 286 ± 137 290 ± 
159*
410 ± 94 428 ± 202 444 ± 184 481 ± 
123
469 ± 76
Glucose 
(mg/dL)
149 ± 84 149 ± 53 206 ± 71 160 ± 35 139 ± 36 138 ± 48 177 ± 47 185 ± 69
CRP (mg/L) 177 ± 91 194 ± 110 215 ± 98 118 ± 53 182 ± 124 241 ± 105 239 ± 85 150 ± 108
AST (UI/L) 102 ± 99 86 ± 86 80 ± 64 48 ± 36 53 ± 41 51 ± 45 37 ± 33 37 ± 17
ALT (UI/L) 46.5 ± 
51.4
40.3 ± 
44.1
49.1 ± 
52.8
45.9 ± 57.0 36.6 ± 29.7 32.2 ± 
25.0
25.7 ± 
20.6
77.0 ± 
157.8
GGT (UI/L) 90.8 ± 
107.9
89.5 ± 
166.3
77.4 ± 
134.2
129.9 ± 
116.0
122.9 ± 
120.0
92.3 ± 
103.0
75.8 ± 
75.2
103.4 ± 
67.7
Bilirubin 
(mg/dL)
2.1 ± 0.7 2.4 ± 0.6 2.8 ± 0.8 3.0 ± 0.8 1.3 ± 0.4 1.3 ± 0.4 1.4 ± 0.3 1.6 ± 0.8
Data are mean ± SEM
CRP = C-reactive protein; AST = Aspartate transaminase; ALT = Alanine transaminase; GGT = γ-glutamyl transpeptidase
*P = 0.024 vs. MCT/LCT at the same timepointBarbosa et al. Critical Care 2010, 14:R5
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and 36% vs. 70% for < 300 (P = 0.015; γ2 test)). Conversely
the proportion of patients with PO2/FiO2 >300 at Day 6
was significantly higher in the fish oil group than the
MCT/LCT group (P = 0.015; γ2 test). No other differences
in gas exchange parameters were seen between the two
groups (Table 5).
Clinical outcomes
Days of ventilation and length of stay in the ICU were not
different between the two treatment groups (Table 6).
The fish oil group tended to have a shorter length of hos-
pital stay than the control group (22 ± 7 vs. 55 ± 16 days;
P = 0.079; Table 6). This tendency remained when age
and glucose supply were adjusted for (P  = 0.062) and
became significant when age, glucose supply and SAPS II
at entry were adjusted for (P = 0.038). Three patients died
within the course of the intervention (one in the MCT/
LCT group and two in the fish oil group); all died from
multiple organ failure. When data for these three patients
who died within the first five days was excluded, length of
stay remained shorter in the fish oil group, but the differ-
ence was not significant (P = 0.078 and P = 0.130 and
0.070 after adjustments; Table 6). A further five patients
died after the completion of the intervention period but
before Day 28 (three in the MCT/LCT group and two in
the fish oil group). When data for these five patients were
also excluded, length of stay was significantly shorter in
the fish oil group (P = 0.044), although this significance
was lost after adjustment for age and glucose supply (P =
0.068) or for age, glucose supply and SAPS II at entry (P =
0.057). Mortality was not different between groups,
although 28 day mortality tended to be lower in the fish
oil group (Table 6).
Discussion
This study set out to evaluate the effects of a lipid emul-
sion containing a mixture of MCT, soybean oil and fish
oil on plasma phospholipid fatty acid profile, inflamma-
tory mediators in plasma and produced by LPS-stimu-
lated whole blood, routine biochemical and physiological
markers, gas exchange and clinical outcomes in septic
patients in the ICU. The control group received a 50:50
mix of MCT and soybean oil. This is the first study of this
fish oil containing lipid emulsion (that is, Lipoplus) in
septic patients in the ICU, although it has been used pre-
viously in post-surgery patients [17-19,34,35]. In these
latter patients, Lipoplus was found to decrease produc-
tion or concentration of inflammatory eicosanoids
[17,34] and cytokines [17] and to reduce length of hospi-
tal stay [18]. A different fish oil containing lipid emulsion
Table 5: Gas exchange parameters in the two treatment groups
Fish oil group MCT/LCT group
Admissio
n
(n = 13)
Day 1
(n = 13)
Day 2
(n = 13)
Day 6
(n = 11)
Admissio
n
(n = 10)
Day 1
(n = 10)
Day 2
(n = 10)
Day 6
(n = 10)
pH 7.27 ± 
0.15
7.38 ± 
0.11
7.41 ± 
0.12
7.42 ± 
0.06
7.37 ± 
0.09
7.38 ± 
0.11
7.44 ± 
0.06
7.43 ± 0.1
Lactate 
(mmol/L)
3.2 ± 1.8 4.0 ± 1.7 4.5 ± 4.8 1.9 ± 0.7 2.7 ± 1.9 3.3 ± 1.9 2.4 ± 1.2 3.1 ± 2.7
PO2 
(mm Hg)
198 ± 121 138 ± 45 127 ± 42 132 ± 44 178 ± 80 136 ± 42 145 ± 33 112 ± 38
PCO2 
(mm Hg)
78 ± 125 39 ± 7 41 ± 6 48 ± 8* 36 ± 8 39 ± 10 40 ± 8 40 ± 8
PO2/FiO2 269 ± 125 248 ± 81 253 ± 102 331 ± 
71**
262 ± 132 252 ± 125 299 ± 80 245 ± 107
PEEP 
(cm H20)
5 (5, 7) 5 (5, 7) 5 (5, 7) 5 (5, 9) 5 (5, 6) 5 (5, 7) 5 (5, 6) 5 (5, 8)
Data are mean ± SEM, apart from PEEP values, which are median and interquartile range.
PO2 = partial pressure of oxygen; PCO2 = partial pressure of carbon dioxide; FiO2 = fraction of inspired oxygen; PEEP = positive end-expiratory 
pressure; *P = 0.033 vs. MCT/LCT group at the same timepoint (Student's t-test with equal variances not assumed; P = 0.016 after adjusting 
for age and glucose supply; P = 0.027 after adjusting for age, glucose supply and SAPS II at entry); **P = 0.047 vs. MCT/LCT group at the same 
timepoint (Student's t-test with equal variances not assumed; P = NS after adjusting for age and glucose supply or for age, glucose supply 
and SAPS II at entry).Barbosa et al. Critical Care 2010, 14:R5
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(Omegaven) has also been used in post-surgery patients
where it decreased production or concentration of
inflammatory eicosanoids [36] and cytokines [16],
improved immune function [15,16] and improved clinical
outcomes [15,16,37]. Omegaven has also been used in
septic patients [21,22], in critically ill ICU patients [24]
and in patients with severe acute pancreatitis [25]. In
some of these studies, use of Omegaven was associated
with decreased inflammatory markers [21,22,25] and
improved respiratory function [25]. Heller et al. [23] used
Omegaven in a heterogeneous group of patients includ-
ing post-surgical, septic and trauma patients and identi-
fied a dose-dependent reduction in mortality predicted
from SAPS II score at entry. However, a recent study
reported no effect of parenteral nutrition including Ome-
gaven on inflammatory markers, or on clinical outcomes
including infections, ventilation requirement, or ICU or
hospital stay in critically ill ICU patients [24].
The current study found that five-day infusion of a
MCT, soybean oil, fish oil mixture providing 6.4 g fish oil/
day (equivalent to 2.3 g EPA plus DHA/d), increased EPA
in the plasma phospholipid PC by an average of 3.8-fold,
with no significant effect on DHA content and that this
was associated with improved gas exchange and a ten-
dency towards a shorter length of hospital stay. These are
important findings since they indicate that the use of
such an emulsion in this group of patients will improve
clinical outcomes in comparison with what is seen with
the more standard mix of MCT and soybean oil.
The increase in EPA content of PC is consistent with
the recent report of a 2.4-fold increase in EPA in plasma
phospholipids in healthy subjects receiving this same
emulsion over a period of five days [29]. Likewise the lack
of a significant change in either in DHA or arachidonic
acid in plasma PC seen in the current study is consistent
with what is reported by Simoens et al. [29]. These obser-
vations would suggest that any clinical benefit seen from
the emulsion is due to EPA rather than DHA.
The tendency towards a reduction in length of hospital
stay seen here (Table 6) was not a result of shorter ICU
stay, and is consistent with findings in post-surgery
patients receiving parenteral fish oil [15,16,18]. A previ-
ous study using a different lipid emulsion in ICU patients
reports reduced ICU stay with higher fish oil administra-
tion [23] but this study was not controlled and relied
upon historical data for comparison. Thus, this is the first
randomised, controlled study reporting reduced length of
hospital stay in septic ICU patients as a result of use of a
fish oil containing lipid emulsion. The average dose of
fish oil administered in the current study (6.4 g/day or
0.09 g/kg/d) is consistent with the dose that Heller et al.
[23] found to be clinically favourable (>0.1 g/kg/d).
Table 6: Clinical outcomes in the two treatment groups
Fish oil group
(n = 13)
MCT/LCT group
(n = 10)
Ventilated days 10 ± 4 11 ± 4
(excluding three patients who died in <5 
days)
(11 ± 5) (12 ± 4)
ICU stay (days) 12 ± 4 13 ± 4
(excluding three patients who died in <5 
days)
(14 ± 5) (14 ± 4)
Length of hospital stay (days) 22 ± 7* 55 ± 16
(excluding three patients who died in <5 
days)
25 ± 8** 61 ± 17
(excluding all eight patients who died) 28 ± 9*** 82 ± 19
five day mortality 15% (2 out of 13) 10% (1 out of 10)
28 day mortality 31% (4 out of 13) 40% (4 out of 10)
Data are mean ± SEM, apart from mortality values
*P = 0.079 vs. MCT/LCT (Student's t-test with equal variances not assumed; P = 0.062 after adjusting for age and glucose supply; P = 0.038 after 
adjusting for age, glucose supply and SAPS II at entry);
**P = 0.078 vs. MCT/LCT (Student's t-test with equal variances not assumed; P = 0.130 after adjusting for age and glucose supply; P = 0.070 
after adjusting for age, glucose supply and SAPS II at entry);
***P = 0.044 vs. MCT/LCT (Student's t-test with equal variances not assumed; P = 0.068 after adjusting for age and glucose supply; P = 0.057 
after adjusting for age, glucose supply and SAPS II at entry)Barbosa et al. Critical Care 2010, 14:R5
http://ccforum.com/content/14/1/R5
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The current study identified a benefit of parenteral fish
oil on gas exchange (Table 5). This is consistent with the
recent report by Wang et al. [25] using parenteral fish oil
in severe acute pancreatitis patients and with findings in
acute respiratory distress syndrome patients receiving
enteral fish oil [26]. The mechanism by which n-3 fatty
acids improve respiratory function is not entirely clear,
but recent work in the fat-1 mouse, which endogenously
synthesizes n-3 fatty acids from dietary n-6 fatty acids,
provides new information on this [38]. When exposed to
LPS intratracheally, fat-1 mice showed reduced leukocyte
invasion, protein leakage and inflammatory mediator
(thromboxane B2, macrophage inflammatory protein-2)
levels in lavage fluid compared with wild type mice. Fur-
thermore ventilator compliance was improved in the fat-1
mice. This study shows a close link between anti-inflam-
matory effects of n-3 fatty acids, in this case seen at the
level of the lung, and improved respiratory function.
Patients receiving parenteral fish oil showed more of a
marked reduction in plasma IL-6 concentration than
those in the MCT/LCT group and they also showed a
smaller reduction in the anti-inflammatory cytokine IL-
10. These findings concur with observations in post-sur-
gery patients where plasma IL-6 concentrations were
lower with parenteral fish oil [16,17]. These changes in
plasma inflammatory markers may be part of the mecha-
nism that explains the clinical benefits seen in this study.
Differences in plasma TNF-α and IL-1β concentrations
between the two groups were small, although significant.
In contrast to the effects on some plasma cytokines,
parenteral fish oil did not affect LPS-stimulated produc-
tion of inflammatory mediators from whole blood cul-
tures. This contrasts with the observation of Mayer et al.
[22] in septic ICU patients that LPS-stimulated produc-
tion of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8)
by purified monocytes was lower in the fish oil group.
However, the amount of fish oil and n-3 fatty acids used
by Mayer et al. was much greater than the amount used in
the current study (35 vs. 6.4 g fish oil/d; approximately 10
vs. 2.3 g EPA plus DHA/d). This may explain the differ-
ence in findings between the two studies.
In the current study the whole blood cultures
responded well to LPS stimulation: the response to LPS
increased with time in both groups. This is consistent
with the recent observations of Kirchhoff et al. [39] who
showed increased numbers of cytokine-positive mono-
cytes following LPS stimulation of whole blood taken
f r o m  p a t i e n t s  w i t h  s e v e r e  m u l t i p l e  i n j u r i e s  o v e r  t h e
period 24 to 72 hours post-admission. Likewise, Heidecke
et al. [40] demonstrated that in sepsis survivors there is
an increase in LPS-stimulated production of IL-1β and
IL-10 by monocytes over time. This recovery in cellular
response appears to be associated with improved clinical
outcome [39,40]. The observation that a poor inflamma-
tory response of cultured cells taken early in sepsis is
associated with poor patient outcome [39,40] seems to
conflict with the many observations that a poor outcome
is associated with higher concentrations of inflammatory
cytokines in the circulation [41-43]. Thus there seems to
be a miss-match between circulating pro- and anti-
inflammatory cytokine concentrations which are elevated
early in sepsis and the ability of leukocytes to produce
pro- and anti-inflammatory cytokines which is impaired
early in sepsis. Indeed, the current study indicates that, as
plasma cytokine concentrations decline over time, the
ability of leukocytes to produce those same cytokines
when stimulated with LPS ex vivo increases. This seem-
ingly paradoxical observation may be explained by con-
sidering the regulatory processes that occur to control
inflammatory cytokine release. A strong inflammatory
stimulus in vivo will lead to inflammatory cytokine pro-
duction with an elevation in plasma cytokine concentra-
tions. However , this will lead to negative feedback, for
example inhibition of monocyte nuclear factor κB activa-
tion [44,45]. Therefore, upon restimulation ex vivo, the
monocytes are less responsive [46]. Hence monocytes
isolated from blood at a time when there is a high con-
centration of cytokines may show a low cytokine
response when stimulated and vice versa.
The anti-inflammatory properties of n-3 fatty acids
have been described and discussed in detail elsewhere
[11,47,48]. The mechanisms involved include effects at
the membrane level, on signal transduction pathways
leading to transcription factor activation and altered pat-
terns of gene expression, and on the pattern of lipid medi-
ator generation. The discovery of resolvins generated
from both EPA and DHA [49] has focussed attention on
resolution of inflammation as a mechanism of action of
n-3 fatty acids and on the differential effects of EPA and
DHA on inflammatory processes. In the current study
status of EPA, but not DHA, was increased in plasma PC,
suggesting that the effects seen are due to EPA. EPA has
been shown to decrease production of inflammatory
eicosanoids and cytokines [see [11]] and is the precursor
of inflammation resolving resolvin E1 [49]. Thus EPA
may exert effects on both the generation of inflammatory
mediators and on the resolution of inflammatory pro-
cesses.
Whatever the mechanism(s) involved, this study dem-
onstrates that a parenteral nutrition regimen including
fish oil at the level used here does not impair the recovery
of the ex vivo response of monocytes, but enhances the
reduction in plasma IL-6 and diminishes the reduction in
plasma IL-10 concentrations seen in the control group.
Given that poor outcome is associated both with high
plasma concentrations of inflammatory cytokines,
including IL-6 [41-43] and with impaired ex vivo mono-Barbosa et al. Critical Care 2010, 14:R5
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cyte responses to LPS [39,40], the overall effects of fish oil
seen in the current study appear to be of benefit.
Limitations of this study are its relatively small sample
size, the difference in age between the two treatment
groups (the average age of patients in the fish oil group
was higher than in the MCT/LCT group), and the higher
glucose supply in the fish oil group. However, despite the
small sample size, significant effects on plasma phospho-
lipid EPA content, plasma cytokines, and gas exchange
parameters were observed. In order to account for the
differences in age and glucose supply between the two
groups, these were controlled for in statistical analysis of
cytokines, gas exchange parameters and clinical out-
comes. Even after accounting for the differences in age
and glucose supply between the groups, effects of lipid
emulsion on plasma cytokines and on gas exchange
parameters remained significant and the trend for an
effect on length of hospital stay was not altered.
Conclusions
Inclusion of fish oil in parenteral nutrition provided to
septic ICU patients increases plasma EPA status and this
is associated with more marked changes in some cytok-
ines in plasma, improved gas exchange and a trend
towards reduced length of hospital stay.
Key messages
• Including fish oil in the parenteral nutrition regimen
received by septic ICU patients modified plasma IL-6
and IL-10 concentrations.
• Parenteral fish oil improved gas exchange in septic
ICU patients.
• Parenteral fish oil decreased length of hospital stay
in septic ICU patients.
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